Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.

@article{Atkinson1995ProphylacticGI,
  title={Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.},
  author={Kerry M Atkinson and Chris Arthur and Ken Bradstock and Bj\org Dale and K. J. Downs and John O Gibson and Maciej Golenia and J Ho and Douglas Joshua and Clemens Juttner},
  journal={Bone marrow transplantation},
  year={1995},
  volume={16 3},
  pages={401-5}
}
A multi-centre Australasian study of the efficacy of prophylactic ganciclovir in 88 recipients of marrow allografts at high risk for post-transplant cytomegalovirus (CMV) disease was conducted. The actuarial incidence of CMV disease was 10% in 74 recipients of HLA-identical family member transplants given ganciclovir but was 33% in 14 recipients of HLA-identical unrelated donor transplants given more immune-suppression pre- and post-transplant (P = 0.006). CMV disease developed in 4 of the 14… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Advances in Allogeneic Hematopoietic Stem Cell Transplantation

Cancer Treatment and Research • 1999
View 7 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…